ARIAD Pharmaceuticals
 | |
| Public | |
| Traded as | NASDAQ: ARIA |
| Industry | Pharmaceuticals, biotechnology |
| Founded | 1991 |
| Headquarters | Cambridge, MA, United States |
Key people |
Harvey Berger, Chairman & CEO<b/r>Timothy P. Clackson, President of Research and Development and Chief Scientific Officer |
| Products |
Ridaforolimus (Under development) Ponatinib (FDA approved, trade name Iclusig) Brigatinib (Under development) |
| Revenue |
 US$178.98M (FY 2010)[1] |
|
US$104.90M (FY 2010)[1] | |
|
US$85.25M (FY 2010)[1] | |
| Total assets |
 US$50.4M (FY 2010)[2] |
Number of employees | 125 (2011) |
| Slogan | Leading the pathway to better cancer therapies |
| Website | www.ariad.com |
ARIAD Pharmaceuticals, Inc. is an oncology company founded in 1991 and headquartered in Cambridge, Massachusetts. On December 14, 2012 the FDA approved Ariad Pharmaceutical’s leukemia drug Iclusig for patients with all forms of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or unable to tolerate other tyrosine kinase therapies on the market.
Company history
Ariad has strong partnerships with Merck and is engaged in the discovery, development, and commercialization of medicines for cancer patients. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States and Europe. The company is also developing Iclusig for other blood cancers and solid tumors, such as gastrointestinal stromal tumors, acute myeloid leukemia, and certain forms of non-small cell lung cancer; and various investigator-sponsored trials in indications, including first line and second line CML, acute myeloid leukemia, non-small cell lung cancer, and medullary thyroid cancer. In addition, its product pipeline consists of Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising non-small cell lung cancer; and Ridaforolimus, an investigational mTOR inhibitor for various types of cancers. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus.
On February 21, 2014 Ariad Pharmaceuticals announced the appointment of Sarissa Capital’s Alexander J. Denner, Ph.D. to a two-year term on the Company’s Board of Directors. Previously, Dr. Denner served as a senior managing director at Carl Icahn's Icahn Capital and is currently Ariad’s second-largest shareholder.
On May 15, 2014, Ariad’s Board of Directors enacted an amendment to its Section 382 Rights Agreement allowing investment firm BlackRock, Inc. the right to acquire more than 4.99% of the common stock in the company.
In July 2015, the company announced it was due to receive up to $200 million through a royalty financing deal with PDL BioPharma on future sales of ponatinib.[3]
Products
FDA-approved products
Products under development
- Ridaforolimus (formerly Deforolimus, partnered with Merck)
- Brigatinib (formerly AP26113)